Unlike HER-2, where expression levels are routinely measured by fluorescent in situ hybridisation or immunohistochemistry in clinical settings, a technique to quantitatively measure IGF1R level in tumour specimens has not yet been subjected to rigorous study. This evidence concerns the gene ERBB2 and neoplasm.